Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Enrollment for Allon Clinical Trial Hits Halfway Mark

May 19, 2011 7:09 am | News | Comments

Allon Therapeutics Inc. has updated the progress of a Phase 2/3 clinical trial that is evaluating the company's lead neuroprotective drug candidate, davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.

TOPICS:

Japan's Takeda Buying Nycomed for $13.6 Billion

May 19, 2011 6:19 am | by Tomoko A. Hosaka, Associated Press | News | Comments

Takeda Pharmaceutical Co. said it will buy Switzerland's Nycomed for $13.6 billion, in an all-cash deal that is the largest ever overseas takeover by a Japanese pharmaceutical company.

TOPICS:

inVentiv Health to Acquire PharmaNet

May 19, 2011 6:14 am | News | Comments

inVentiv Health announced it has signed a definitive agreement to purchase PharmaNet Development Group, extending its global presence to nearly 40 countries and enhancing both its early- and late-stage clinical development capabilities.

TOPICS:
Advertisement

Antibody Microarray

May 19, 2011 5:53 am | Drug Discovery & Development | Product Releases | Comments

The QuantiPlasma Array, a monoclonal antibody microarray from Randox Pharma Services, is designed to assess the level of multiple proteins simultaneously in human plasma.

TOPICS:

argen-x Initiates Second Preclinical Program

May 19, 2011 5:49 am | News | Comments

arGEN-X announced that  ARGX-110, a human antibody specific for an undisclosed, clinically validated cell surface receptor has moved into formal pre-clinical development, less than 18 months since beginning its operations. 

TOPICS:

SuppreMol Licenses Interleukin 3 Antibody

May 19, 2011 5:46 am | News | Comments

SuppreMol GmbH, a biopharmaceutical company developing therapeutics for the treatment of autoimmune diseases, has agreed to in-license an antibody directed against interleukin 3 (IL-3).

TOPICS:

Isotyping ELISA Kit

May 19, 2011 5:43 am | Drug Discovery & Development | Product Releases | Comments

A mouse monoclonal antibody (mAb) isotyping ELISA kit from Eagle Biosciences, Inc. uses a 96-well ELISA format for identification of both mouse immunoglobulin subclass and light chain.

TOPICS:

AbD Serotec Licenses Seven Diagnostic HuCAL Antibodies

May 19, 2011 5:35 am | News | Comments

MorphoSys AG announced that Proteomika, a Spanish biotechnology company specializing in biomarker discovery, has licensed seven diagnostic HuCAL-antibodies from MorphoSys's AbD Serotec Division.

TOPICS:
Advertisement

Regulus Therapeutics Expands Executive Team

May 19, 2011 5:28 am | News | Comments

Regulus Therapeutics announced the appointment of Mary Glanville as senior vice president of human capital and Christopher Aker as senior director of legal affairs and secretary.

TOPICS:

Ludwig Institute and Polaris Explore Potential Cancer Therapy

May 19, 2011 5:22 am | News | Comments

Ludwig Institute for Cancer Research (LICR) and Polaris Group announced a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase.

TOPICS:

Seaside Therapeutics Reviews Fragile X Syndrome Options

May 19, 2011 5:13 am | News | Comments

Seaside Therapeutics has published a review paper detailing the evolving scientific and drug development for fragile X syndrome, the most common inherited form of intellectual disability and most common known cause of autism.

TOPICS:

Drosha Could be Target for Cervical Cancer Drug

May 19, 2011 5:08 am | News | Comments

Cancer Research UK scientists have discovered that a common gene fault in cervical cancer cells triggers a ripple of molecular signals, which makes the disease more aggressive.

TOPICS:

Phase I/II Clinical Trial Results for Lupus Patients

May 19, 2011 5:03 am | News | Comments

Neovacs published the initial results of a phase I/II study with IFN?-Kinoid in lupus patients that highlights the safety, immunogenicity, and the pharmacodynamics of the therapy, according to a report by Neovacs.

TOPICS:

MS Patients Show Relapse Rate Reduction in Coptimize Study

May 19, 2011 4:58 am | News | Comments

Teva Pharmaceutical reported preliminary data from two studies, Coptimize and QualiCop.

TOPICS:

Epstein-Barr Could Be MS Risk Factor

May 18, 2011 11:54 am | News | Comments

The Epstein-Barr virus, belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus, is one of the environmental factors that might cause multiple sclerosis.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading